Fomivirsen
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy category |
|
| Routes of administration | Intravitreal injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C204H263N63O114P20S20 |
| Molar mass | 6682.4 g/mol g·mol−1 |
  (what is this?) (verify) | |
Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was licensed by the FDA for CMV in Aug 1998.
It is a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:
- 5'-GCG TTT GCT CTT CTT CTT GCG-3'
Mechanism
It is an oligonucleotide[1] that blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the template segment of a key CMV gene UL123, which encodes the CMV protein IE2. It was the first antisense antiviral approved by the FDA.[2]
Administration
It is available as an intraocular injection in a concentration of 6.6 mg/mL (CMV commonly manifests as chorioretinitis).[3]
See also
References
- ^ Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMC 105584. PMID 9559825.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Roush W (May 1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327.
- ^ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. p. 817. ISBN 0-07-145153-6.
Further reading
- Grillone, LR; Lanz, R (2001). "Fomivirsen". Drugs Today (Barc). 37 (4): 245–255. PMID 12768225.
- Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet. 41 (4): 255–60. doi:10.2165/00003088-200241040-00002. PMID 11978144.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol. 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781.
{{cite journal}}:|first1=has generic name (help) - Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care. 4 (10): 14–6. PMID 11365956.
External links
- MedlinePlus DrugInfo uspdi-203675
- Diseases Database (DDB): 31313
- "Vitravene (Fomivirsen) Drug Information: Uses, Side Effects, Drug Interactions and Warning". RxList. 2004-12-08. Retrieved 2009-05-20.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help)
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |